

June 14, 2023

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor,  
Plot No. C-1, G- Block,  
Bandra - Kurla Complex, Bandra (East)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

**Sub: Disclosure under Regulation 30 (6) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 (6) read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find below the details of Analyst/Institutional meet(s):

Date	Particulars	Location
15 <sup>th</sup> June 2023	RPG Annual Investor Conference 2023	Mumbai

The presentation to be made by the Company at the conference is enclosed herewith.

Kindly take the above on record.

Thanking you,

Yours Sincerely,

For RPG Life Sciences Limited

**RAJESH**

**RAMESH**

**SHIRAMBEKAR**

Digitally signed by  
RAJESH RAMESH  
SHIRAMBEKAR  
Date: 2023.06.14  
16:46:54 +05'30'

Rajesh Shirambekar

Head – Legal & Company Secretary





hello happiness

# Annual Investor Conference 2023

RPG Life Sciences

June 15, 2023



## Disclaimer

---


This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the "Company"), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. If you are participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

# RPG Life Sciences: An Integrated Pharmaceutical Company

RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



**Leader** in Immunosuppressants



**9** Therapies represented by High Equity Brands



**50+** Markets Presence




**3** Manufacturing Facilities



**1200+** Employees


## FY 2022-23: A Milestone Year







4

\* Domestic Formulations internal growth (FY23) | \*\*IQVIA TSA MAT March 23

## Margins: A Trajectory of y-o-y expansion continues



## Key Financial Metrics : A Trajectory of Strong y-o-y Growth




6


\* Approved by Board

## Key Ratios (ROCE, ROE) : A Trajectory of y-o-y uptrend

### ROCE %




### ROE %



Company continues to remain Debt-free







# Journey of RPG Life Sciences



# ESG Progress Update FY23

### Environment Goals

-  **Carbon Emission**  
10% reduction in FY23
-  **Energy Consumption**  
8% reduction in FY23
-  **Waste Management**  
Hazardous Waste Reduction by 15% in FY23
-  **Water Management**  
7% reduction in water consumption FY23

### Social Goals


-  **Diversity & Inclusion**  
50% increase in gender diversity in FY23
-  **Product Responsibility**  
Strict Quality Vigil
-  **Employee Well-being**  
Co-morbidity control through a 40-point checklist

### Governance Goals

-  **Data Integrity**  
Digitalization across Plants
-  **Cybersecurity**  
IT assets security through EDR tool
-  **Industry Best Practices**  
In Marketing, Sales, Quality, Procurement etc.

# The Journey Ahead: Benchmark Performance to Scale-up

## 7 Pillars identified





**hello happiness**